Abstract

REVIEW ON NOVEL FORMULATION AND DEVELOPMENT USED IN TREATMENT OF BILE DUCT CANCER

Gangasagar H. Gadekar*, Nakul P. Kathar, Dr. Gajanan S. Sanap and Pooja D. Pawar

ABSTRACT

Cancer is characterised by proliferation of cells that managed to evade central endogeneous control mechanism. Cancer are grouped according to their organ or tissue of origin, but increasingly also based on molecular characteristics of the respective cancer cells. Due to rapid technological advances of the last years, it is now possible to analyse the molecular makeup of different cancer types in detail within short time periods. The accumulating knowledge about development and progression of cancer can be used to develop more precise diagnostic and more effective and/or less cancer toxic therapies. In the long run, the aim is to offer to every tumor patient a therapeutic regime that is tailored to his individual disease and position, In an optimal way. Bile duct cancer is also called cholangiocarcinoma. It is rare types of cancer that arise in the bile ducts.The bile ducts are small tubes that combine the liver and gallbladder to the small bowel. It carries fluid named bile that helps to break down fats in food.

Keywords: Bile duct cancer, liposomal irinotecan, Chemotherapy, Nanoparticles, liposomes, silymarin, folfirinox, Cholangiocarcinoma.